Senti Biosciences uses synthetic biology to engineer gene circuits that improve cell and gene therapy products. Funds will be used to apply Senti Biosciences' gene circuit platform to develop an internal therapeutic pipeline of allogeneic CAR-NK candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma.

Senti Biosciences' gene circuits are novel and proprietary combinations of DNA that enable cells to sense their environment, perform logic, and to instruct cells to produce therapeutic proteins for enhanced safety and efficacy

Proceeds from the financing round will be used to support the development of preclinical oncology programs and expanding Senti Biosciences gene circuit technology platform across different modalities and therapeutic areas. Senti Biosciences also plans to scale up clinical manufacturing.

Bayer, Atara collaborate on CAR T-cell therapies
Bayer and Atara Biotherapeutics have entered into an agreement to research, develop, manufacture, and license mesothelin-directed chimeric antigen receptor...

Bayer acquires Asklepios to advance gene therapies
Bayer has agreed to pay $2 billion to acquire Asklepios BioPharmaceutical, a U.S.-based biotechnology company specializing in gene therapies.

Specifica transfers antibody discovery platform to Bayer
Specifica announced the transfer of its Generation 3 antibody libraries to Bayer under an agreement that will enable the company to develop antibody-based...